BioSpace News Archive

ViTel Net and Language Services Associates (LSA) are excited to announce a new platform integration that enables clinicians to immediately add an interpreter to a telehealth video encounter within the existing clinical workflow, regardless of physician or patient location – with just three clicks.

Dow is launching its call for entries for the 2020 Packaging Innovation Awards.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Duke University investigators have dosed the first patient in a proof-of-concept Phase 1b study to evaluate GlycoMimetics’ novel GMI-1359 drug candidate in patients with advanced breast cancer.

Universal Health Services, Inc. announced that its Board of Directors voted to pay a cash dividend of $0.20 per share on March 16, 2020 to shareholders of record as of March 2, 2020.

Next Generation Technology Includes Features that Automatically Adjust to Patient Needs, and Offers Physicians Heart Failure Diagnostic Insights DUBLIN, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced it has received CE ( Conformité Européenne ) Mark for its Cobalt™ and Crome™ portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D).

InCrowd, life science industry leader for real-time, high-quality primary market intelligence, ended 2019 with a record fourth-quarter performance and continued strong growth, capping an extraordinary year as measured by revenue, customers, and market impact.

miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced new efficacy and safety data from the ATLL arm of its ongoing Phase 1 clinical trial of cobomarsen, which will be presented at the 12th Annual T-Cell Lymphoma Forum in La Jolla, CA,

FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the achievement of clinical development milestones for two of its exclusively-licensed, clinical-stage products to Boehringer Ingelheim (BI) and Bristol-Myers Squibb Company (BMS) (NYSE:BMY).

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2019 update and financial results on Thursday, February 13 at 8:30 a.m. ET.

Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced the company has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) in the amount of $3.9 million to support development of TLY012 for treatment of chronic pancreatitis.